{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:51:42Z","timestamp":1772578302334,"version":"3.50.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>21-Hydroxylase deficiency (21-OHD), the most common form of congenital adrenal hyperplasia, is an autosomal recessive disorder caused by pathogenic variants in <jats:italic toggle=\"yes\">CYP21A2<\/jats:italic>. Although this disorder has been known for several decades, many challenges related to its monitoring and treatment remain to be addressed. The present review is written to describe an overview of biochemical monitoring of this entity, with particular focus on overnight fasting urine pregnanetriol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>We have conducted a decade-long research project to investigate methods of monitoring 21-OHD in children. Our latest studies on this topic have recently been published. One is a review of methods for monitoring 21-OHD. The other was to demonstrate that measuring the first morning PT level may be more practical and useful for biochemical monitoring of 21-OHD. The first morning pregnanetriol (PT), which was previously reported to reflect a long-term auxological data during the prepubertal period, correlated more significantly than the other timing PT in this study, with 17-OHP, before the morning medication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In conclusion, although the optimal method of monitoring this disease is still uncertain, the use of overnight fasting urine pregnanetriol (P3) as a marker of 21-OHD is scientifically sound and may be clinically practical.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001369","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:10:15Z","timestamp":1717517415000},"page":"456-462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Biochemical monitoring of 21-hydroxylase deficiency: a clinical utility of overnight fasting urine pregnanetriol"],"prefix":"10.1097","volume":"36","author":[{"given":"Yukihiro","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Itonaga","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oita University Faculty of Medicine, Oita"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo"},{"name":"Department of Pediatrics, Keio University School of Medicine, Keio, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Izawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Amano","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1297\/cpe.16.45","article-title":"Pregnanetriol in the range of 1.2-2 1\u200amg\/m2\/day as an index of optimal control in CYP21A2 deficiency","volume":"16","author":"Izawa","year":"2007","journal-title":"Clin Pediatr Endocrinol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1297\/cpe.17.75","article-title":"The range of 2.2\u20133.3\u200amg\/gCr of pregnanetriol in the first morning urine sample as an index of optimal control in CYP21 deficiency","volume":"17","author":"Izawa","year":"2008","journal-title":"Clin Pediatr Endocrinol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"808254","DOI":"10.3389\/fendo.2021.808254","article-title":"First morning pregnanetriol and 17-hydroxyprogesterone correlated significantly in 21-hydroxylase deficiency","volume":"12","author":"Itonaga","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1102741","DOI":"10.3389\/fendo.2023.1102741","article-title":"Monitoring treatment in pediatric patients with 21-hydroxylase deficiency","volume":"14","author":"Itonaga","year":"2023","journal-title":"Front Endocrinol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMra021561","article-title":"Congenital adrenal hyperplasia","volume":"349","author":"Speiser","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1297\/cpe.2022-0009","article-title":"Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)","volume":"31","author":"Ishii","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-19-0905","article-title":"Abiraterone acetate treatment lowers 11-oxygenated androgens","volume":"182","author":"Wright","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: Results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250730","first-page":"1","article-title":"ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/en.2019-00117","article-title":"A long-acting neutralizing monoclonal ACTH antibody blocks corticosterone and adrenal gene responses in neonatal rats","volume":"160","author":"Gehrand","year":"2019","journal-title":"Endocrinology"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"A350","DOI":"10.1210\/jendso\/bvaa046.690","article-title":"MON-176 discovery and identification of late stage selective nonpeptide ACTH antagonists for the treatment of Cushing's disease, ectopic ACTH secreting tumors, and congenital adrenal hyperplasia","volume":"4","author":"Kusnetzow","year":"2020","journal-title":"J Endocr Soc"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"A354","DOI":"10.1210\/jendso\/bvaa046.699","article-title":"OR19-03 effects of nonpeptide orally bioavailable ACTH antagonists on adrenal gland size and function in rats","volume":"4","author":"Markison","year":"2020","journal-title":"J Endocr Soc"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1210\/jc.2009-0942","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation","volume":"94","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2265.2002.01645.x","article-title":"Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome","volume":"57","author":"Manoli","year":"2002","journal-title":"Clin Endocrinol"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000333696","article-title":"Adrenarche and puberty in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"76","author":"Volkl","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7326\/0003-4819-136-4-200202190-00012","article-title":"NIH Conference. future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"136","author":"Merke","year":"2002","journal-title":"Ann Intern Med"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1297\/cpe.24.77","article-title":"Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)","volume":"24","author":"Mass Screening","year":"2015","journal-title":"Clin Pediatr Endocrinol"},{"key":"R25-20250730","first-page":"CD012517","article-title":"Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia","volume":"3","author":"Ng","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1530\/EJE-20-1249","article-title":"International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry","volume":"184","author":"Bacila","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R27-20250730","first-page":"173","article-title":"Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"6","author":"Einaudi","year":"1993","journal-title":"J Pediatr Endocrinol"},{"key":"R28-20250730","first-page":"42","article-title":"Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience","volume":"70","author":"Hoepffner","year":"2008","journal-title":"Horm Res"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1210\/jc.2016-3989","article-title":"11-oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency","volume":"102","author":"Turcu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"bvaa192","DOI":"10.1210\/jendso\/bvaa192","article-title":"11-oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency","volume":"5","author":"Jha","year":"2021","journal-title":"J Endocr Soc"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jcem.86.10.7972","article-title":"Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-15-0064","article-title":"Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers","volume":"173","author":"Debono","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s42000-022-00354-1","article-title":"The utility of annual growth velocity standard deviation scores and measurements of biochemical parameters in long-term treatment monitoring of children with 21-hydroxylase deficiency","volume":"21","author":"Ozdemir Dilek","year":"2022","journal-title":"Horm (Athens)"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-3476(99)70413-0","article-title":"Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples","volume":"134","author":"Bode","year":"1999","journal-title":"J Pediatr"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000315910","article-title":"Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia","volume":"75","author":"Sarafoglou","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1515\/jpem-2014-0303","article-title":"Therapy monitoring in congenital adrenal hyperplasia by dried blood samples","volume":"28","author":"Wieacker","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/jpem-2016-0203","article-title":"Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia","volume":"30","author":"Birkebaek","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"(Pt 1)","key":"R39-20250730","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/000456328702400109","article-title":"Radioimmunoassay of blood-spot 17 alpha-hydroxyprogesterone in the management of congenital adrenal hyperplasia","volume":"24","author":"Robinson","year":"1987","journal-title":"Ann Clin Biochem"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1210\/jc.2003-032235","article-title":"Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia","volume":"89","author":"Minutti","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.steroids.2006.01.015","article-title":"Automated, fast and sensitive quantification of 17 alpha-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line extraction","volume":"71","author":"Rauh","year":"2006","journal-title":"Steroids"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.steroids.2011.07.013","article-title":"Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry","volume":"76","author":"Janzen","year":"2011","journal-title":"Steroids"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1210\/jc.2019-00438","article-title":"Height velocity defined metabolic control in children with congenital adrenal hyperplasia using urinary GC-MS analysis","volume":"104","author":"Kamrath","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1515\/JPEM.2000.13.2.205","article-title":"Correlation of blood-spot 17-hydroxyprogesterone daily profiles and urinary steroid profiles in congenital adrenal hyperplasia","volume":"13","author":"Erhardt","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"154354","DOI":"10.1016\/j.metabol.2020.154354","article-title":"Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia","volume":"112","author":"Kamrath","year":"2020","journal-title":"Metabolism"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"105553","DOI":"10.1016\/j.jsbmb.2019.105553","article-title":"Urinary steroidomic profiles by LC-MS\/MS to monitor classic 21-hydroxylase deficiency","volume":"198","author":"Pussard","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1515\/jpem-2019-0006","article-title":"Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty","volume":"32","author":"Pijnenburg-Kleizen","year":"2019","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:07:09Z","timestamp":1753898829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001369","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}